AstraZeneca (AZN) Given “Buy” Rating at Bryan, Garnier & Co
AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by research analysts at Bryan, Garnier & Co in a research note issued to investors on Friday.
Several other analysts also recently issued reports on the stock. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, September 7th. Barclays set a GBX 6,300 ($84.79) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, September 13th. Goldman Sachs Group reaffirmed a “sell” rating and set a GBX 3,800 ($51.14) price objective on shares of AstraZeneca in a report on Tuesday, October 17th. Liberum Capital reaffirmed a “buy” rating and set a GBX 4,800 ($64.60) price objective on shares of AstraZeneca in a report on Tuesday, September 5th. Finally, Natixis raised shares of AstraZeneca from a “neutral” rating to a “buy” rating and upped their price objective for the stock from GBX 5,000 ($67.29) to GBX 5,738 ($77.23) in a report on Wednesday, September 6th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of GBX 5,169 ($69.57).
Shares of AstraZeneca (LON:AZN) opened at GBX 4,866.50 ($65.50) on Friday. AstraZeneca has a 1 year low of GBX 4,136.50 ($55.67) and a 1 year high of GBX 5,520 ($74.29).
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.